Am­gen's deno­sum­ab shows promise in small, NIH-fund­ed rare bone dis­ease study

Am­gen’s Pro­lia/Xge­va (deno­sum­ab) could have an­oth­er use in a rare bone dis­ease, ac­cord­ing to a small NIH-fund­ed Phase II study, adding to its ap­provals in oth­er bone dis­or­ders as biosim­i­lar com­pe­ti­tion is on its way.

The mon­o­clon­al an­ti­body “sig­nif­i­cant­ly re­duced ab­nor­mal bone turnover in adults” with the rare dis­ease, known as fi­brous dys­pla­sia, ac­cord­ing to the re­sults of the eight-per­son study, car­ried out by the Na­tion­al In­sti­tute of Den­tal and Cran­io­fa­cial Re­search (NID­CR) and the NIH Clin­i­cal Cen­ter. Bone turnover, which oc­curs when old bone is re­placed with new bone, is un­usu­al­ly ac­cel­er­at­ed in those with fi­brous dys­pla­sia and con­tributes to bone ab­nor­mal­i­ties, NIH said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.